Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial ResultsBusiness Wire • 11/14/23
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular DiseaseBusiness Wire • 11/01/23
Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines ConferenceBusiness Wire • 09/26/23
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma CollaborationBusiness Wire • 07/11/23
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca CollaborationBusiness Wire • 05/04/23
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease EventsBusiness Wire • 05/01/23
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor ConferenceBusiness Wire • 04/25/23
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia VeraBusiness Wire • 04/04/23
Silence Therapeutics to Present at Guggenheim's Genomic Medicines and Rare Disease DaysBusiness Wire • 03/29/23
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and DevelopmentBusiness Wire • 03/28/23
Silence Therapeutics: Breaking The Silence On An Under-The-Radar Mid-Stage SiRNA PlatformSeeking Alpha • 03/14/23
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar?Zacks Investment Research • 03/06/23
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023Business Wire • 03/02/23
Silence Therapeutics to Present at SVB Securities Global Biopharma ConferenceBusiness Wire • 02/08/23
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations OfficerBusiness Wire • 02/06/23